Brochure
CRO Solutions for Metabolic & Cardiovascular Diseases
This pamphlet introduces Cyagen’s validated mouse models and full-spectrum CRO services for metabolic and cardiovascular research, including diabetes, obesity, MASH, and atherosclerosis.
Overview
Cyagen offers a comprehensive portfolio of genetically engineered and induced mouse models for metabolic and cardiovascular disease studies. Combined with robust in vivo and in vitro efficacy evaluations, biomarker profiling, histology, and mechanism-of-action assays, these models support preclinical research in obesity, diabetes, MASH, dyslipidemia, and diabetic complications. Case studies validate drug responses across GLP-1R, PCSK9, and dual/triple agonists in translational settings.
Key Insights
Integrated model and CRO solutions for metabolic and cardiovascular research.
- Validated genetic models: db/db, ob/ob, Apoe KO, hPCSK9, hGLP-1R, and more
- Induced models: MASH (HFD+CCl4), STZ, DIO, nephropathy, alcoholic steatohepatitis
- Full-spectrum in vivo evaluations: weight, glucose, insulin sensitivity, histology, lipids
- Case studies covering GLP-1R agonists, siRNA, Semaglutide, and Tirzepatide
- Applicable to T2D, MASH, cardiovascular, renal, and rare metabolic disease research
Unlock Advanced Research Insights with Cyagen’s Resources
Explore an array of valuable resources tailored to enhance your preclinical research. Download mateirals meticulously crafted to provide advanced insights and methodologies. Elevate your research strategies with Cyagen's expertise.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.